Formulation: A solid
Formal Name: 4-[4-[[2-(4-chlorophenyl)-5,5-dimethyl-1-cyclohexen-1-yl]methyl]-1-piperazinyl]-N-[[4-[[(1R)-3-(4-morpholinyl-d8)-1-[(phenylthio)methyl]propyl]amino]-3-[(trifluoromethyl)sulfonyl]phenyl]sulfonyl]-benzamide
Purity: ≥99% deuterated forms (d1-d8)
Formula Markup: C47H47ClD8F3N5O6S3
Formula Weight: 982,7
Shelf life (days): 1460
CAS Number: 1217620-38-6
Notes: ABT-263-d8 is intended for use as an internal standard for the quantification of ABT-263 (Item No. 11500) by GC- or LC-MS. ABT-263 is an inhibitor of the Bcl-2 family proteins Bcl-2, Bcl-xL, and Bcl-W (Kis = is = 550 and 354 nM, respectively). ABT-263 is cytotoxic in a panel of small cell lung cancer (SCLC), leukemia, and lymphoma cell lines with a mean EC50 value of 1 µM. It induces apoptosis in influenza A-infected retinal pigment epithelial cells (EC50 = 0.08 µM).{46183} ABT-263 (100 mg/kg) induces tumor regression in NCI H146 SCLC and RS4;11 acute lymphocytic leukemia (ALL) mouse xenograft models.{24781,24782}
English
Deutsch
